Landscape of vaccine access and health technology assessment role in decision-making process in ASEAN countries
Over the past few years, many innovative vaccines became available that offer protection for diseases which have never been prevented before. While there are several factors that could have an impact on access, the use of health technology assessment (HTA) undoubtedly is also one of the contributing factors. Objectives: To explore the landscape of vaccine access and the role of HTA in new vaccine adoption in Association of Southeast Asian Nations (ASEAN) countries. Results: A great deal of progress has been made in terms of access to new and innovation vaccine in the region. Variation in access to these vaccines comparing between countries, however, is still observed. The use of HTA in supporting new vaccine adoption is still in an early stage especially in Gavi, the Vaccine Alliance-eligible countries. Conclusions: Improving the use of HTA evidences to support decision making could accelerate the efficient adoption of new vaccine in ASEAN region.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
---|---|
Enthalten in: |
Human vaccines & immunotherapeutics - 16(2020), 7 vom: 02. Juli, Seite 1728-1737 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Taychakhoonavudh, Suthira [VerfasserIn] |
---|
Links: |
---|
Themen: |
ASEAN |
---|
Anmerkungen: |
Date Completed 21.06.2021 Date Revised 24.06.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1080/21645515.2020.1769388 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM311526225 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM311526225 | ||
003 | DE-627 | ||
005 | 20231226201557.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1080/21645515.2020.1769388 |2 doi | |
028 | 5 | 2 | |a pubmed24n1038.xml |
035 | |a (DE-627)NLM311526225 | ||
035 | |a (NLM)32574124 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Taychakhoonavudh, Suthira |e verfasserin |4 aut | |
245 | 1 | 0 | |a Landscape of vaccine access and health technology assessment role in decision-making process in ASEAN countries |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 21.06.2021 | ||
500 | |a Date Revised 24.06.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Over the past few years, many innovative vaccines became available that offer protection for diseases which have never been prevented before. While there are several factors that could have an impact on access, the use of health technology assessment (HTA) undoubtedly is also one of the contributing factors. Objectives: To explore the landscape of vaccine access and the role of HTA in new vaccine adoption in Association of Southeast Asian Nations (ASEAN) countries. Results: A great deal of progress has been made in terms of access to new and innovation vaccine in the region. Variation in access to these vaccines comparing between countries, however, is still observed. The use of HTA in supporting new vaccine adoption is still in an early stage especially in Gavi, the Vaccine Alliance-eligible countries. Conclusions: Improving the use of HTA evidences to support decision making could accelerate the efficient adoption of new vaccine in ASEAN region | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a ASEAN | |
650 | 4 | |a Vaccine | |
650 | 4 | |a access | |
650 | 4 | |a expanded program in immunization | |
650 | 4 | |a health technology assessment | |
650 | 4 | |a national immunization program | |
650 | 7 | |a Vaccines |2 NLM | |
700 | 1 | |a Chumchujan, Woralak |e verfasserin |4 aut | |
700 | 1 | |a Hutubessy, Raymond |e verfasserin |4 aut | |
700 | 1 | |a Chaiyakunapruk, Nathorn |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Human vaccines & immunotherapeutics |d 2012 |g 16(2020), 7 vom: 02. Juli, Seite 1728-1737 |w (DE-627)NLM21576823X |x 2164-554X |7 nnns |
773 | 1 | 8 | |g volume:16 |g year:2020 |g number:7 |g day:02 |g month:07 |g pages:1728-1737 |
856 | 4 | 0 | |u http://dx.doi.org/10.1080/21645515.2020.1769388 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 16 |j 2020 |e 7 |b 02 |c 07 |h 1728-1737 |